Recently it was reported that 13 out of 20 patients relapsing after treatment of B-ALL with genetically manipulated T-lymphocytes (chimeric antigen receptor (CAR-T) cells) targeting CD19 developed CD19 negative leukemia even at the clonal level [121,122]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.